tradingkey.logo

Piper Sandler upgrades Myriad to 'overweight' on CEO change

ReutersMar 12, 2025 11:42 AM

Brokerage Piper Sandler upgrades medical test kit maker Myriad Genetics MYGN.O to "overweight" from "neutral"; ups PT by $1 to $12.50

Says stock has "more than rebased" after a 50% decline in the last six months

Says new CEO, Sam Raha, is expected to "reset the business"

Last month, MYGN said CEO Paul Diaz is stepping down

Brokerage believes co's stock has found a bottom around the "1x revenue range", as they think the company's "biggest remaining potential downside is expectations set by a previous CEO"

Co has a "solid core franchise in esoteric testing" with high-margin products that can grow in the high single digits - brokerage

MYGN fell 27.8% in 2024

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI